{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:07:06Z","timestamp":1790856426293,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10585-024-10312-3","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:02:24Z","timestamp":1727067744000},"page":"863-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives"],"prefix":"10.1007","volume":"41","author":[{"given":"Filippo","family":"Merloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Palleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cecconetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Di Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"10312_CR1","doi-asserted-by":"publisher","first-page":"1367159","DOI":"10.1155\/2017\/1367159","volume":"2017","author":"P Kelly","year":"2017","unstructured":"Kelly P, Ma Z, Baidas S, Moroose R, Shah N, Dagan R et al (2017) Patterns of progression in metastatic estrogen receptor positive breast Cancer: an argument for local therapy. Int J Breast Cancer 2017:1367159. https:\/\/doi.org\/10.1155\/2017\/1367159","journal-title":"Int J Breast Cancer"},{"issue":"1","key":"10312_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM et al (2020) Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation. Lancet oncol 21(1):e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"Lancet Oncol"},{"issue":"12","key":"10312_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","volume":"31","author":"PH Patel","year":"2019","unstructured":"Patel PH, Palma D, McDonald F, Tree AC (2019) The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? clin oncol 31(12):824\u2013833. https:\/\/doi.org\/10.1016\/j.clon.2019.05.015","journal-title":"Clin Oncol"},{"key":"10312_CR4","doi-asserted-by":"publisher","unstructured":"Weykamp F, K\u00f6nig L, Seidensaal K, Forster T, Hoegen P, Akbaba S et al (2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front oncol 26:10:987. https:\/\/doi.org\/10.3389\/fonc.2020.00987. eCollection 2020","DOI":"10.3389\/fonc.2020.00987"},{"issue":"22","key":"10312_CR5","doi-asserted-by":"publisher","first-page":"16198","DOI":"10.3390\/ijms242216198","volume":"24","author":"F Raheem","year":"2023","unstructured":"Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L (2023) Metastatic ER\u2009+\u2009breast cancer: mechanisms of resistance and future therapeutic approaches. Int J Mol Sci 24(22):16198. https:\/\/doi.org\/10.3390\/ijms242216198","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10312_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41523-021-00363-0","volume":"7","author":"I Mavrommati","year":"2021","unstructured":"Mavrommati I, Johnson F, Echeverria GV, Natrajan R (2021) Subclonal heterogeneity and evolution in breast cancer. NPJ Breast Cancer 7(1):155. https:\/\/doi.org\/10.1038\/s41523-021-00363-0","journal-title":"NPJ Breast cancer"},{"issue":"13 Supplement","key":"10312_CR7","doi-asserted-by":"publisher","first-page":"CT106","DOI":"10.1158\/1538-7445.am2018-ct106","volume":"78","author":"C Kim","year":"2018","unstructured":"Kim C et al (2018) Abstract CT106: local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib. Cancer Res 78(13 Supplement):CT106\u2013CT106. https:\/\/doi.org\/10.1158\/1538-7445.am2018-ct106","journal-title":"Cancer Res"},{"issue":"34","key":"10312_CR8","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","volume":"32","author":"P Iyengar","year":"2014","unstructured":"Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32(34):3824\u20133830. https:\/\/doi.org\/10.1200\/JCO.2014.56.7412","journal-title":"J Clin Oncol"},{"issue":"3","key":"10312_CR9","doi-asserted-by":"publisher","first-page":"E265","DOI":"10.1016\/j.ijrobp.2021.07.869","volume":"111","author":"C Berghen","year":"2021","unstructured":"Berghen C, Joniau S, Rans K, Poels K, Devos G, Haustermans K et al (2021) Metastasis-directed therapy for oligoprogressive castration-resistant prostate cancer \u2015 preliminary results of the prospective, single-arm MEDCARE trial. IJROBP 111(3):E265\u2013E266. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.869","journal-title":"IJROBP"},{"issue":"6","key":"10312_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10585-021-10126-7","volume":"38","author":"D Pezzulla","year":"2021","unstructured":"Pezzulla D, Macchia G, Cilla S, Buwenge M, Ferro M, Bonome P et al (2021) Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. clin exp metastasis 38(6):519\u2013526. https:\/\/doi.org\/10.1007\/s10585-021-10126-7","journal-title":"Clin Exp metastasis"},{"issue":"6","key":"10312_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung P, Patel S, North SA, Sahgal A, Chu W, Soliman H et al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. eur urol 80(6):693\u2013700. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.026","journal-title":"Eur Urol"},{"issue":"2","key":"10312_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","volume":"5","author":"R Hannan","year":"2022","unstructured":"Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D et al (2022) Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. eur urol oncol 5(2):216\u2013224. https:\/\/doi.org\/10.1016\/j.euo.2021.12.001","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10312_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.clon.2017.04.035","volume":"29","author":"OSH Chan","year":"2017","unstructured":"Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY, Yeung RMW (2017) The role of Radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. clin oncol 29(9):568\u2013575. https:\/\/doi.org\/10.1016\/j.clon.2017.04.035","journal-title":"Clin Oncol"},{"issue":"6","key":"10312_CR14","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/j.cllc.2017.04.002","volume":"18","author":"B Qiu","year":"2017","unstructured":"Qiu B, Liang Y, Li QW, Liu GH, Wang F, Chen ZL et al (2017) Local therapy for oligoprogressive disease in patients with advanced stage non\u2013small-cell lung cancer harboring epidermal growth factor receptor mutation. clin lung cancer 18(6):e369\u2013e373. https:\/\/doi.org\/10.1016\/j.cllc.2017.04.002","journal-title":"Clin lung cancer"},{"issue":"7","key":"10312_CR15","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.3390\/curroncol30070505","volume":"30","author":"B Yan","year":"2023","unstructured":"Yan B, Ramadan S, Jerzak KJ, Louie AV, Donovan E (2023) The effectiveness and safety of stereotactic body Radiation Therapy (SBRT) in the treatment of oligoprogressive breast cancer: a systematic review. curr oncol 30(7):6976\u20136985. https:\/\/doi.org\/10.3390\/curroncol30070505","journal-title":"Curr Oncol"},{"issue":"12","key":"10312_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","volume":"7","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thora Oncol 7(12):1807\u20131814. https:\/\/doi.org\/10.1097\/JTO.0b013e3182745948","journal-title":"J Thora Oncol"},{"key":"10312_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1 - update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"issue":"3","key":"10312_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/cells11030388","volume":"11","author":"H Shao","year":"2022","unstructured":"Shao H, Varamini P (2022) breast cancer bone metastasis: a narrative review of emerging targeted drug delivery systems. cells 11(3):388. https:\/\/doi.org\/10.3390\/cells11030388","journal-title":"Cells"},{"issue":"5","key":"10312_CR19","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/bcr2944","volume":"13","author":"H Sihto","year":"2011","unstructured":"Sihto H, Lundin J, Lundin M, Lehtim\u00e4ki T, Ristim\u00e4ki A, Holli K et al (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast cancer Res 13(5):R87. https:\/\/doi.org\/10.1186\/bcr2944","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10312_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.cr.7290266","volume":"15","author":"JJ Yin","year":"2005","unstructured":"Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15(1):57\u201362. https:\/\/doi.org\/10.1038\/sj.cr.7290266","journal-title":"Cell Res"},{"key":"10312_CR21","doi-asserted-by":"publisher","first-page":"1133828","DOI":"10.3389\/fonc.2023.1133828","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B (2023) Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Fron Oncol 13:1133828. https:\/\/doi.org\/10.3389\/fonc.2023.1133828","journal-title":"Fron Oncol"},{"issue":"6","key":"10312_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2967\/jnumed.119.234260","volume":"61","author":"GJR Cook","year":"2020","unstructured":"Cook GJR, Goh V (2020) Molecular imaging of bone metastases and their response to therapy. J Nucl Med 61(6):799\u2013806. https:\/\/doi.org\/10.2967\/jnumed.119.234260","journal-title":"J Nucl Med"},{"issue":"12","key":"10312_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2967\/jnumed.118.211102","volume":"59","author":"LM Peterson","year":"2018","unstructured":"Peterson LM, O\u2019Sullivan J, Wu Q, Novakova-Jiresova A, Jenkins I, Lee JH et al (2018) Prospective study of serial18F-FDG PET and18F-fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer. J Nucl Med 59(12):1823\u20131830. https:\/\/doi.org\/10.2967\/jnumed.118.211102","journal-title":"J Nucl Med"},{"key":"10312_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580277","author":"C Liu","year":"2020","unstructured":"Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song S et al (2020) Dual Tracers of 16\u03b1-[18F]fluoro-17\u03b2-Estradiol and [18F]fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR+\/HER2- metastatic breast cancer. Front oncol. https:\/\/doi.org\/10.3389\/fonc.2020.580277","journal-title":"Front oncol"},{"issue":"2","key":"10312_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1078-0432.CCR-16-0362","volume":"23","author":"BF Kurland","year":"2017","unstructured":"Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM et al (2017) Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER\u2009+\u2009breast cancer. Clin Cancer Res 23(2):407\u2013415. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0362","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10312_CR26","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1200\/JCO.22.00400","volume":"40","author":"JJL Van Geel","year":"2020","unstructured":"Van Geel JJL, Boers J, Elias SG, Glaudemans AWJM, De Vries EFJ, Hospers GAP et al (2020) Clinical validity of 16\u03b1-[18F]Fluoro-17\u03b2-Estradiol positron emission tomography\/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast Cancer. J Clin Oncol 40(31):3642\u20133652. https:\/\/doi.org\/10.1200\/JCO.22.00400","journal-title":"J Clin Oncol"},{"key":"10312_CR27","unstructured":"Stereotactic Body Radiation Therapy and FES PET\/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT06260033"},{"issue":"1","key":"10312_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA (2021) ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23(1):85. https:\/\/doi.org\/10.1186\/s13058-021-01462-3","journal-title":"Breast Cancer Res"},{"issue":"24","key":"10312_CR29","doi-asserted-by":"publisher","first-page":"11471","DOI":"10.1158\/0008-5472.CAN-07-2496","volume":"67","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE (2007) Clonal selection of metastasis within the life history of a tumor. Cancer Res 67(24):11471\u201311475. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2496","journal-title":"Cancer Res"},{"issue":"11","key":"10312_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, De La Pierga Jy T et al (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23(11):1367\u20131377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1","journal-title":"Lancet Oncol"},{"key":"10312_CR31","doi-asserted-by":"crossref","unstructured":"Grigoryeva ES, A.Tashireva L, Alifanov VV, Savelieva OE, Vtorushin SV, Zavyalova MV et al (2022) Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer. Sci Rep ;12(1)","DOI":"10.1038\/s41598-022-25609-0"},{"issue":"5","key":"10312_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13058-014-0440-8","volume":"16","author":"M Giuliano","year":"2014","unstructured":"Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN et al (2014) Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16(5):440. https:\/\/doi.org\/10.1186\/s13058-014-0440-8","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10312_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/annonc\/mdp262","volume":"21","author":"U De Giorgi","year":"2010","unstructured":"De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC et al (2010) Circulating tumor cells and bone metastases as detected by FDG-PET\/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33\u201339. https:\/\/doi.org\/10.1093\/annonc\/mdp262","journal-title":"Ann Oncol"},{"issue":"8","key":"10312_CR34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2967\/jnumed.110.076455","volume":"51","author":"U De Giorgi","year":"2010","unstructured":"De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM et al (2010) 18F-FDG PET\/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nuc Med 51(8):1213\u20131218. https:\/\/doi.org\/10.2967\/jnumed.110.076455","journal-title":"J Nuc Med"},{"key":"10312_CR35","doi-asserted-by":"publisher","first-page":"e2100512","DOI":"10.1200\/po.21.00512","volume":"6","author":"MA Gouda","year":"2022","unstructured":"Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S et al (2022) Longitudinal monitoring of circulating Tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis Oncol 6:e2100512. https:\/\/doi.org\/10.1200\/po.21.00512","journal-title":"JCO Precis Oncol"},{"key":"10312_CR36","doi-asserted-by":"publisher","first-page":"910544","DOI":"10.3389\/fonc.2022.910544","volume":"12","author":"T Ueno","year":"2022","unstructured":"Ueno T (2022) Surgical management of metastatic breast cancer: a mini review. Front oncol 12:910544. https:\/\/doi.org\/10.3389\/fonc.2022.910544","journal-title":"Front Oncol"},{"key":"10312_CR37","doi-asserted-by":"publisher","first-page":"100584","DOI":"10.1016\/j.ctro.2023.100584","volume":"39","author":"M Terlizzi","year":"2023","unstructured":"Terlizzi M, Limkin E, Sellami N, Louvel G, Blanchard P (2023) Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature. Clin transl radiat oncol 39:100584. https:\/\/doi.org\/10.1016\/j.ctro.2023.100584","journal-title":"Clin Transl Radiat Oncol"},{"issue":"Suppl 6","key":"10312_CR38","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.21037\/jtd.2016.03.14","volume":"8","author":"MWK Tsang","year":"2016","unstructured":"Tsang MWK (2016) Stereotactic body radiotherapy: current strategies and future development. J Thorac Dis 8(Suppl 6):S517\u2013S527. https:\/\/doi.org\/10.21037\/jtd.2016.03.14","journal-title":"J Thorac Dis"},{"issue":"10422","key":"10312_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2023","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J et al (2023) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403(10422):171\u2013182. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3","journal-title":"Lancet"},{"key":"10312_CR40","doi-asserted-by":"publisher","unstructured":"David SP, Siva S, Bressel M, Tan J, Hanna GG, Alomran RK et al (2023) Stereotactic ablative body radiotherapy (SABR) for oligoprogressive ER-positive breast cancer (AVATAR): a phase II prospective multicenter trial. IJROBP https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.033","DOI":"10.1016\/j.ijrobp.2023.08.033"},{"issue":"6","key":"10312_CR41","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.esmoop.2022.100629","volume":"7","author":"V Di Lauro","year":"2022","unstructured":"Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C et al (2022) Health-related quality of life in breast cancer patients treated with CDK4\/6 inhibitors: a systematic review. ESMO Open 7(6):100629. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100629","journal-title":"ESMO Open"},{"issue":"4","key":"10312_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10585-022-10167-6","volume":"39","author":"L Nicosia","year":"2022","unstructured":"Nicosia L, Figlia V, Ricottone N, Cuccia F, Mazzola R, Giaj-Levra N et al (2022) Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients. Clin exp metastasis 39(4):581\u2013588. https:\/\/doi.org\/10.1007\/s10585-022-10167-6","journal-title":"Clin Exp Metastasis"},{"key":"10312_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","volume":"161","author":"H Tan","year":"2021","unstructured":"Tan H, Cheung P, Louie AV, Myrehaug S, Niglas M, Atenafu EG et al (2021) Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol 161:159\u2013165. https:\/\/doi.org\/10.1016\/j.radonc.2021.06.012","journal-title":"Radiother Oncol"},{"issue":"15","key":"10312_CR44","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1002\/cam4.4068","volume":"10","author":"NA Wijetunga","year":"2021","unstructured":"Wijetunga NA, dos Anjos CH, Zhi WI, Robson M, Tsai CJ, Yamada Y et al (2021) Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. Cancer Med 10(15):5163\u20135174. https:\/\/doi.org\/10.1002\/cam4.4068","journal-title":"Cancer Med"},{"key":"10312_CR45","doi-asserted-by":"publisher","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L et al Overall survival with ribociclib plus letrozole in advanced breast cancer. N Eng J Med 386(10):942\u2013950 https:\/\/doi.org\/10.1056\/NEJMoa2114663","DOI":"10.1056\/NEJMoa2114663"},{"issue":"1","key":"10312_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/JAMAONCOL.2019.4782","volume":"6","author":"GW Sledge","year":"2019","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X et al (2019) The Effect of Abemaciclib Plus Fulvestrant on overall survival in hormone Receptor\u2013Positive, ERBB2-Negative breast Cancer that progressed on endocrine Therapy\u2014MONARCH 2: a Randomized Clinical Trial. JAMA Oncol 6(1):116\u2013124. https:\/\/doi.org\/10.1001\/JAMAONCOL.2019.4782","journal-title":"JAMA Oncol"},{"issue":"20","key":"10312_CR47","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/nejmoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N et al (2018) Overall survival with Palbociclib and fulvestrant in advanced breast Cancer. N Eng J Med 379(20):1926\u20131936. https:\/\/doi.org\/10.1056\/nejmoa1810527","journal-title":"N Eng J Med"},{"key":"10312_CR48","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.ctrv.2023.102586","volume":"119","author":"C Becherini","year":"2023","unstructured":"Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G et al (2023) Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: a systematic review and meta-analysis. Canc Treat Rev 119:102586. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102586","journal-title":"Canc Treat Rev"},{"key":"10312_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.radonc.2022.10.023","volume":"177","author":"L Visani","year":"2022","unstructured":"Visani L, Livi L, Ratosa I, Orazem M, Ribnikar D, Saieva C et al (2022) Safety of CDK4\/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Radiother Oncol 177:40\u201345. https:\/\/doi.org\/10.1016\/j.radonc.2022.10.023","journal-title":"Radiother Oncol"},{"key":"10312_CR50","unstructured":"Radiation Therapy Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis. ClinicalTrials.gov. Available:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT03691493"},{"key":"10312_CR51","unstructured":"Local Treatment in ER-positive\/HER2-negative Oligo-metastatic Breast Cancer. ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03750396"},{"issue":"4","key":"10312_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-0","journal-title":"Lancet Oncol"},{"issue":"10075","key":"10312_CR53","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389(10075):1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"10312_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-5058-6","author":"E Lidbrink","year":"2019","unstructured":"Lidbrink E, Chmielowska E, Otremba B, Bouhlel A, Lauer S, Liste Hermoso M et al (2019) A real-world study of cardiac events in >\u20093700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-018-5058-6","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10312_CR55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J et al (2021) Past, Present, and Future of Radiation-Induced Cardiotoxicity: refinements in Targeting, Surveillance, and risk stratification. JACC CardioOncol 3(3):343\u2013359. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.007","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10312_CR56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12032-014-0891-x","volume":"31","author":"I Meattini","year":"2014","unstructured":"Meattini I, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M et al (2014) Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. Med Oncol 31(4):891. https:\/\/doi.org\/10.1007\/s12032-014-0891-x","journal-title":"Med Oncol"},{"issue":"16","key":"10312_CR57","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","volume":"27","author":"MY Halyard","year":"2009","unstructured":"Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 27(16):2638\u20132644. https:\/\/doi.org\/10.1200\/JCO.2008.17.9549","journal-title":"J Clin Oncol"},{"issue":"2","key":"10312_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canrad.2016.10.002","volume":"21","author":"Z Ajgal","year":"2017","unstructured":"Ajgal Z, de Percin S, Di\u00e9ras V, Pierga JY, Campana F, Fourquet A et al (2017) Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and\/or metastatic breast cancer: Assessment of early toxicity. Cancer Radiother 21(2):114\u2013118. https:\/\/doi.org\/10.1016\/j.canrad.2016.10.002","journal-title":"Cancer Radiother"},{"issue":"5","key":"10312_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.canrad.2020.06.037","volume":"25","author":"S Ben Dhia","year":"2021","unstructured":"Ben Dhia S, Loap S, Loirat P, Vincent-Salomon D, Cao A, Escalup K L, et al (2021) Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity. Cancer Radiother 25(5):424\u2013431. https:\/\/doi.org\/10.1016\/j.canrad.2020.06.037","journal-title":"Cancer Radiother"},{"issue":"7","key":"10312_CR60","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M et al (2019) Trastuzumab Emtansine for residual invasive HER2-Positive breast Cancer. N Eng J Med 380(7):617\u2013628. https:\/\/doi.org\/10.1056\/nejmoa1814017","journal-title":"N Eng J Med"},{"issue":"19","key":"10312_CR61","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/nejmoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab Emtansine for HER2-Positive advanced breast Cancer. N Engl J Med 367(19):1783\u20131791. https:\/\/doi.org\/10.1056\/nejmoa1209124","journal-title":"N Engl J Med"},{"issue":"12","key":"10312_CR62","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/COC.0000000000000769","volume":"43","author":"Z Zolcs\u00e1k","year":"2020","unstructured":"Zolcs\u00e1k Z, Loirat D, Fourquet A, Kirova YM (2020) Adjuvant Trastuzumab Emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast Cancer: single-center preliminary results. Am J Clin Oncol 43(12):895\u2013901. https:\/\/doi.org\/10.1097\/COC.0000000000000769","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"10312_CR63","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","volume":"33","author":"IE Krop","year":"2015","unstructured":"Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C et al (2015) Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol 33(10):1136\u20131142. https:\/\/doi.org\/10.1200\/JCO.2014.58.7782","journal-title":"J Clin Oncol"},{"issue":"10371","key":"10312_CR64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5.)","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371):105\u2013117. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.)","journal-title":"Lancet"},{"issue":"1","key":"10312_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Eng J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Eng J Med"},{"issue":"7","key":"10312_CR66","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/nejmoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA et al (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive metastatic breast Cancer. N Eng J Med 382(7):597\u2013609. https:\/\/doi.org\/10.1056\/nejmoa1914609","journal-title":"N Eng J Med"},{"issue":"9","key":"10312_CR67","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/nejmoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) pembrolizumab for early triple-negative breast cancer. N Eng J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/nejmoa1910549","journal-title":"N Eng J Med"},{"issue":"3","key":"10312_CR68","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/nejmoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C et al (2022) pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Eng J Med 387(3):217\u2013226. https:\/\/doi.org\/10.1056\/nejmoa2202809","journal-title":"N Eng J Med"},{"issue":"22","key":"10312_CR69","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/nejmoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H et al (2018) atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Eng J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/nejmoa1809615","journal-title":"N Eng J Med"},{"issue":"4","key":"10312_CR70","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cllc.2021.01.012","volume":"22","author":"MD Mattes","year":"2021","unstructured":"Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM et al (2021) A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non\u2013small cell lung cancer. Clin Lung Cancer 22(4):268\u2013273. https:\/\/doi.org\/10.1016\/j.cllc.2021.01.012","journal-title":"Clin lung cancer"},{"issue":"2","key":"10312_CR71","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","volume":"98","author":"A Bang","year":"2017","unstructured":"Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A et al (2017) Multicenter evaluation of the tolerability of combined treatment with pd-1 and ctla-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys 98(2):344\u2013351. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.02.003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10312_CR72","doi-asserted-by":"crossref","unstructured":"Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ et al (2022) A phase 1 trial of concurrent or sequential Ipilimumab, Nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC Study. In: J Thorac Oncol","DOI":"10.1016\/j.jtho.2021.08.019"},{"issue":"9","key":"10312_CR73","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F et al (2023) checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors. JAMA Oncol 9(9):1205\u20131213. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2132","journal-title":"JAMA Oncol"},{"key":"10312_CR74","unstructured":"Pre-op pembro\u2009+\u2009radiation therapy in breast cancer (P-RAD)- clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT04443348"},{"key":"10312_CR75","unstructured":"Evaluate the Clinical benefit of a post-operative treatment associating radiotherapy\u2009+\u2009Nivolumab\u2009+\u2009ipilimumab versus radiotherapy\u2009+\u2009capecitabine for triple negative breast cancer patients with residual disease. ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT03818685?cond=NCT03818685&rank=1"},{"issue":"4","key":"10312_CR76","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/CNCR.32599","volume":"126","author":"AY Ho","year":"2020","unstructured":"Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A et al (2020) A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer 126(4):850\u2013860. https:\/\/doi.org\/10.1002\/CNCR.32599","journal-title":"Cancer"},{"key":"10312_CR77","doi-asserted-by":"publisher","unstructured":"Zhang Z, Liu X, Chen D, Yu J (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Therapy 17. https:\/\/doi.org\/10.1038\/s41392-022-01102-y","DOI":"10.1038\/s41392-022-01102-y"},{"issue":"1","key":"10312_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06480-5","volume":"192","author":"O Gumusay","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS (2022) Immunotherapy toxicity: identification and management. Breast Cancer Res Treat 192(1):1\u201317. https:\/\/doi.org\/10.1007\/s10549-021-06480-5","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"10312_CR79","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/nejmoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Eng J Med 384(25):2394\u20132405. https:\/\/doi.org\/10.1056\/nejmoa2105215","journal-title":"N Eng J Med"},{"issue":"6","key":"10312_CR80","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/nejmoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/nejmoa1706450","journal-title":"N Engl J Med"},{"issue":"8","key":"10312_CR81","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/nejmoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH et al (2018) Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Eng J Med 379(8):753\u2013763. https:\/\/doi.org\/10.1056\/nejmoa1802905","journal-title":"N Eng J Med"},{"issue":"10","key":"10312_CR82","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.33737","volume":"149","author":"P Loap","year":"2021","unstructured":"Loap P, Loirat D, Berger F, Cao K, Ricci F, Jochem A et al (2021) Combination of olaparib with radiotherapy for triple-negative breast cancers: one-year toxicity report of the RADIOPARP phase I trial. Int J cancer 149(10):1828\u20131832. https:\/\/doi.org\/10.1002\/ijc.33737","journal-title":"Int J Cancer"},{"issue":"25","key":"10312_CR83","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"issue":"1","key":"10312_CR84","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14(1):e28\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(12)70510-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"10312_CR85","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.21037\/tcr-20-2119","volume":"10","author":"M Hu","year":"2021","unstructured":"Hu M, Shao B, Ran R, Li H (2021) Prognostic factors for patients with metastatic breast cancer: a literature review. Transl Cancer Res 10(4):1644\u20131655. https:\/\/doi.org\/10.21037\/tcr-20-2119","journal-title":"Transl Cancer Res"},{"key":"10312_CR86","doi-asserted-by":"publisher","first-page":"175883592210869","DOI":"10.1177\/17588359221086916","volume":"14","author":"LA Huppert","year":"2022","unstructured":"Huppert LA, Gumusay O, Rugo HS (2022) Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol 14:17588359221086916. https:\/\/doi.org\/10.1177\/17588359221086916","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10312_CR87","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M et al (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium. Lancet Oncol 24(3):e121\u2013e132. https:\/\/doi.org\/10.1016\/S1470-2045(22)00752-5","journal-title":"Lancet Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10312-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T20:03:03Z","timestamp":1734984183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10312"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10312-3","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. De Giorgi received honoraria for advisory boards or speaker fees for Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, Institutional research grants from AstraZeneca, Sanofi and Roche. Dr. Michela Palleschi has received advisory board or speaker fees from Novartis, Lilly, Astrazeneca. Dr. Filippo Merloni has received advisory board or speaker fees from Novartis, Lilly, Astrazeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}